U.S. Markets open in 1 hr 2 mins

Aclaris Therapeutics, Inc. (ACRS)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
2.5400+0.1500 (+6.28%)
At close: 4:00PM EDT

2.4000 -0.14 (-5.51%)
Before hours: 8:15AM EDT

Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close2.3900
Open2.3700
Bid2.4500 x 800
Ask0.0000 x 3100
Day's Range2.3500 - 2.6200
52 Week Range0.7000 - 3.3400
Volume278,409
Avg. Volume672,350
Market Cap108.825M
Beta (5Y Monthly)1.34
PE Ratio (TTM)N/A
EPS (TTM)-2.4280
Earnings DateAug 07, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    Aclaris Therapeutics to Present at Upcoming Investor Conferences

    WAYNE, Pa., Sept. 01, 2020 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced that management will participate in the following upcoming virtual investor conferences: * H.C. Wainwright & Co. 22nd Annual Global Investment Conference. On Tuesday, September 15, 2020 at 12:30 p.m. ET, Dr. Neal Walker, the President and CEO of Aclaris, will present a company overview. Management will be available September 15th throughout the day for virtual one-on-one meetings with investors who are registered to attend the conference.   * Cantor Virtual Global Healthcare Conference. On Thursday, September 17, 2020 at 10:40 a.m. ET., Dr. Walker will participate in a fireside chat. Management will be available September 17th throughout the day for virtual one-on-one meetings with investors who are registered to attend the conference.A live audio webcast of each presentation may be accessed through the Events page under the Investors section of Aclaris’ website, www.aclaristx.com. An archived version of each webcast will be available for 30 days.About Aclaris Therapeutics, Inc.Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates to address the needs of patients with immuno-inflammatory diseases who lack satisfactory treatment options. The company has a multi-stage portfolio of drug candidates powered by a robust R&D engine exploring protein kinase regulation. For additional information, please visit www.aclaristx.com.Aclaris Contact  investors@aclaristx.com

  • Aclaris (ACRS) Upgraded to Buy: Here's What You Should Know
    Zacks

    Aclaris (ACRS) Upgraded to Buy: Here's What You Should Know

    Aclaris (ACRS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank 2 (Buy).

  • Aclaris Therapeutics (ACRS) Reports Q2 Loss, Tops Revenue Estimates
    Zacks

    Aclaris Therapeutics (ACRS) Reports Q2 Loss, Tops Revenue Estimates

    Aclaris (ACRS) delivered earnings and revenue surprises of 17.65% and 64.21%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?